David Olmos
Impact in
- Pulmonary and Respiratory Medicine top 0.1%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Oncology top 0.5%
- PARP inhibition in cancer therapy
Papers in
-
- Prostate Cancer Treatment and Research 115
- Sarcoma Diagnosis and Treatment 14
- Prostate Cancer Diagnosis and Treatment 10
- Oncology 50
- PARP inhibition in cancer therapy 33
- Inflammatory Biomarkers in Disease Prognosis 6
- Co-authors
- Johann Sebastian De Bono (56 shared papers)Fred Saad (21 shared papers)Shahneen Kaur Sandhu (26 shared papers)Joaquı́n Mateo (12 shared papers)Gerhardt Attard (23 shared papers)Ian Robert Judson (16 shared papers)Stan B. Kaye (19 shared papers)Kim N. Chi (10 shared papers)
- Journals
- Annals of Oncology (45 papers)European Urology (14 papers)Journal of Clinical Oncology (14 papers)British Journal of Cancer (13 papers)Clinical Cancer Research (12 papers)
- Partner nations
- SpainUnited KingdomUnited States
In The Last Decade
David Olmos
198 papers receiving 15.3k citations
David Olmos's Hit Papers
Peers
Comparison fields: 5 of 121
- Pulmonary and Respiratory Medicine 8.4k
- Oncology 3k
- Cancer Research 1.5k
- Genetics 1.2k
- Statistics and Probability 485
Countries citing papers authored by David Olmos
This map shows the geographic impact of David Olmos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Olmos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Olmos more than expected).
Fields of papers citing papers by David Olmos
This network shows the impact of papers produced by David Olmos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Olmos. The network helps show where David Olmos may publish in the future.
Co-authors
The 25 scholars most cited alongside David Olmos, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 202 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Olaparib for Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2020 | 1776 |
| 2 | Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer Hit paper breakdown → | 2018 | 1036 |
| 3 | Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer Hit paper breakdown → | 2013 | 676 |
| 4 | Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2020 | 614 |
| 5 | Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer Hit paper breakdown → | 2009 | 501 |
| 6 | 2011 | 492 | |
| 7 | Characterization of ERG , AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer Hit paper breakdown → | 2009 | 476 |
| 8 | Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2015 | 335 |
| 9 | 2010 | 328 | |
| 10 | PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2019 | 313 |
| 11 | 2014 | 302 | |
| 12 | 2009 | 290 | |
| 13 | Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial Hit paper breakdown → | 2021 | 269 |
| 14 | 2015 | 265 | |
| 15 | Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2023 | 248 |
| 16 | 2013 | 247 | |
| 17 | 2020 | 217 | |
| 18 | 2008 | 214 | |
| 19 | 2012 | 212 | |
| 20 | 2016 | 194 |
About David Olmos
David Olmos is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Statistics and Probability, Cancer Research and Genetics, having authored 202 papers that have together received 15.6k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (115 papers), PARP inhibition in cancer therapy (33 papers), Statistical Methods in Clinical Trials (15 papers), Sarcoma Diagnosis and Treatment (14 papers), BRCA gene mutations in cancer (13 papers), Prostate Cancer Diagnosis and Treatment (10 papers), Inflammatory Biomarkers in Disease Prognosis (6 papers) and Cancer Genomics and Diagnostics (6 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (8.4k citations), Oncology (3k citations), Cancer Research (1.5k citations), Genetics (1.2k citations) and Statistics and Probability (485 citations). David Olmos has collaborated with scholars based in Spain, United Kingdom and United States. Frequent co-authors include Johann Sebastian De Bono, Fred Saad, Shahneen Kaur Sandhu, Joaquı́n Mateo, Gerhardt Attard, Ian Robert Judson, Stan B. Kaye, Kim N. Chi, Carrie A. Adelman and Antoine Thiery-Vuillemin. Their work appears in journals such as Annals of Oncology, European Urology, Journal of Clinical Oncology, British Journal of Cancer and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.